Exelixis reported 4Q earnings of 12 cents a share compared to a loss of 18 cents last year.
Exelixis entered into separate cancer collaborations with Bristol-Myers Squibb and Roche.
- Investor's Business Daily•2 days ago
Exelixis is teaming up with Bristol-Myers Squibb and Roche to test its Cabometyx and their immuno-oncology drugs in liver and bladder cancer.
RHHBY : Summary for ROCHE HLDG LTD SPONS - Yahoo Finance
Roche Holding AG (RHHBY)
Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
|Day's Range||30.24 - 30.60|
|52 Week Range||25.25 - 33.77|
Trade prices are not sourced from all markets
|PE Ratio (TTM)||21.91|
|Dividend & Yield||1.02 (3.36%)|
|1y Target Est||N/A|